Navinci Launches Omni Kit
Analysis based on 8 articles · First reported Apr 29, 2026 · Last updated Apr 29, 2026
The launch of Navinci's Omni kit is expected to positively impact the biotechnology and medical research markets by providing advanced tools for studying protein function. This innovation could lead to new drug discoveries and a better understanding of disease mechanisms, potentially benefiting companies involved in these sectors.
Navinci, a Swedish biotech company, announced the launch of its new Omni kit on April 29, 2026. This kit is designed to revolutionize the study of protein function in tissue using proprietary in situ proximity ligation assay (isPLA) technology. Omni enables the simultaneous detection of up to 9 target pairs, revealing protein-protein interactions, post-translational modifications, and single protein targets. The kit is available as a ready-to-use product and a full-service offering. A proof-of-concept study, conducted in collaboration with Uppsala University, demonstrated Omni's high sensitivity and specificity. This technology aims to enhance understanding of health, disease progression, and drug mechanisms.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard